33.60 USD
+0.17
0.51%
At close Dec 20, 4:00 PM EST
After hours
33.74
+0.14
0.42%
1 day
0.51%
5 days
-0.24%
1 month
0.75%
3 months
-17.65%
6 months
-17.57%
Year to date
-10.42%
1 year
-7.16%
5 years
-43.20%
10 years
-38.12%
 

About: In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, antiviral, and vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Employees: 70,200

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

93% more call options, than puts

Call options by funds: $200M | Put options by funds: $104M

13% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 78

1% more funds holding

Funds holding: 871 [Q2] → 881 (+10) [Q3]

2% more capital invested

Capital invested by funds: $12.4B [Q2] → $12.6B (+$290M) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 10 [Q2] → 10 (+0) [Q3]

0.3% less ownership

Funds ownership: 7.77% [Q2] → 7.47% (-0.3%) [Q3]

4% less repeat investments, than reductions

Existing positions increased: 302 | Existing positions reduced: 316

Research analyst outlook

We haven’t received any recent analyst ratings for GSK.

Financial journalist opinion

Based on 21 articles about GSK published over the past 30 days

Positive
Proactive Investors
2 days ago
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, significantly improved progression-free survival (PFS) in first-line advanced ovarian cancer.
GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer
Positive
Reuters
2 days ago
GSK's cancer drugs meet progression-free survival goal in late-stage trial
GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.
GSK's cancer drugs meet progression-free survival goal in late-stage trial
Positive
Zacks Investment Research
4 days ago
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.
GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli
Positive
Proactive Investors
6 days ago
GSK passes three significant milestones with new cancer drug given a double boost
GSK PLC (LSE:GSK, NYSE:GSK) has announced significant progress in its oncology pipeline, achieving three milestones. The European Medicines Agency (EMA) has issued a positive opinion recommending the expanded approval of Jemperli (dostarlimab) with chemotherapy for first-line treatment of advanced or recurrent endometrial cancer.
GSK passes three significant milestones with new cancer drug given a double boost
Positive
Zacks Investment Research
1 week ago
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.
GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?
Neutral
GlobeNewsWire
1 week ago
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Neutral
GlobeNewsWire
1 week ago
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis London, UK, December 10, 2024 – Relation, an industry leader in deploying computation and experimentation to drug discovery, today announced two multi-program strategic collaborations with GSK. The collaborations will focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis.
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis
Positive
Proactive Investors
1 week ago
GSK says blood cancer drug shows dramatic survival gains in key trial
GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep (belantamab mafodotin) significantly extended survival in a pivotal trial. The drug, combined with two other therapies, reduced the risk of death by 42% compared to a rival treatment from Johnson & Johnson (NYSE:JNJ), according to results presented at the American Society of Hematology's annual meeting.
GSK says blood cancer drug shows dramatic survival gains in key trial
Positive
Reuters
1 week ago
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.
GSK's drug combo shown to cut risk of death by 42% in type of blood cancer
Positive
Zacks Investment Research
1 week ago
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.
FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD
Charts implemented using Lightweight Charts™